BioCentriq Inc., the Newark-based cell and gene therapy contract development and manufacturing organization, has cut the ribbon on a new good manufacturing practice facility in South Brunswick, it announced Friday.
The CDMO, which got its start at New Jersey Innovation Institute and was purchased by South Korean company GC in May, said the two new clean rooms and supporting infrastructure add to the current pilot plant operations at Princeton Corporate Plaza. BioCentriq already has a clean room facility at its Newark site.
“We are thrilled to be opening an additional GMP manufacturing site as part of BioCentriq’s expansion plan,” CEO Haro Hartounian said in a prepared statement. “With this added capacity, BioCentriq can take on more projects to help biotech companies bring their products from bench to market, which is what we do best.”
The new facility, which is designed to accommodate a variety of cell and gene therapy projects, will provide additional capacity to support market demand, BioCentriq said.
BioCentriq said it is planning further expansion in 2023 with additional manufacturing suites, supporting labs and infrastructure, and more.
“Our plan is to continue expanding along with industry needs,” Amy Lamperti, senior vice president of commercialization, said in a statement. “Right now, there is a massive need for cell and gene therapy CDMOs with both the appetite and expertise in development and clinical manufacturing of promising allogeneic and autologous cell therapies. We’re proud to fill that gap by continuing to support these novel therapeutics that have the potential to help patients live better, healthier lives.”
